{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:03Z","timestamp":1792552263986,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ncl.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T13:08:52Z","timestamp":1737551332000},"page":"229-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biomarkers in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Sarah M.","family":"Brooker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Gonzalez-Latapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"s1","key":"10.1016\/j.ncl.2024.12.005_bib1","first-page":"S3","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"Pt 5","key":"10.1016\/j.ncl.2024.12.005_bib3","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1474-4422(23)00124-2","article-title":"alpha-synuclein seed amplification and its uses in Parkinson's disease","volume":"22","author":"Berg","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s10072-022-06014-x","article-title":"Real-time quaking-induced conversion assay is accurate for Lewy body diseases: a meta-analysis","volume":"43","author":"Wang","year":"2022","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"Alpha-synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-A systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-023-00627-5","article-title":"CSF alpha-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson's disease","volume":"10","author":"Brockmann","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-014-1284-0","article-title":"Cutaneous neuropathy in Parkinson's disease: a window into brain pathology","volume":"128","author":"Doppler","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.005_bib14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mds.26293","article-title":"Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy","volume":"30","author":"Doppler","year":"2015","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.0000000000002919","article-title":"The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease","volume":"87","author":"Gibbons","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1369\/0022155420960250","article-title":"Phosphorylated alpha-synuclein within cutaneous autonomic nerves of patients with Parkinson's disease: the implications of sample thickness on results","volume":"68","author":"Wang","year":"2020","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.ncl.2024.12.005_bib17","article-title":"Optimization of the detection method for phosphorylated alpha-synuclein in Parkinson disease by skin biopsy","volume":"11","author":"Liu","year":"2020","journal-title":"Front Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/acn3.669","article-title":"Cervical skin denervation associates with alpha-synuclein aggregates in Parkinson disease","volume":"5","author":"Melli","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2024.0792","article-title":"Skin biopsy detection of phosphorylated alpha-synuclein in patients with synucleinopathies","volume":"331","author":"Gibbons","year":"2024","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.005_bib20","doi-asserted-by":"crossref","first-page":"e1529","DOI":"10.1212\/WNL.0000000000206772","article-title":"Cutaneous alpha-synuclein signatures in patients with multiple system atrophy and Parkinson disease","volume":"100","author":"Gibbons","year":"2023","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","article-title":"The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy","volume":"113","author":"Lee","year":"2006","journal-title":"J\u00a0Neural Transm"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma alpha-synuclein predicts cognitive decline in Parkinson's disease","volume":"88","author":"Lin","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib23","article-title":"Plasma pS129-alpha-Synuclein is a surrogate biofluid marker of motor severity and progression in Parkinson's disease","volume":"8","author":"Lin","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ncl.2024.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149620","article-title":"Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of Parkinson's pathology","volume":"703","author":"Ishiguro","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1042\/BST20220204","article-title":"Propagation of Parkinson's disease by extracellular vesicle production and secretion","volume":"50","author":"Shippey","year":"2022","journal-title":"Biochem Soc Trans"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.005_bib28","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/mds.29497","article-title":"Extracellular vesicles for the diagnosis of Parkinson's disease: systematic review and meta-analysis","volume":"38","author":"Xylaki","year":"2023","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.005_bib29","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological alpha-synuclein in blood","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105307","article-title":"Potential exosome biomarkers for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"25","author":"Kim","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ncl.2024.12.005_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded alpha-synuclein in blood years before the diagnosis of Parkinson's disease","author":"Kluge","year":"2024","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","article-title":"Neuronally derived extracellular vesicle alpha-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib33","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.28984","article-title":"Alpha-synuclein radiotracer development and in\u00a0vivo imaging: recent advancements and new perspectives","volume":"37","author":"Alzghool","year":"2022","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.005_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090847","article-title":"Alpha-synuclein PET tracer development-an overview about current efforts","volume":"14","author":"Korat","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib35","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","article-title":"The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","volume":"14","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.005_bib36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25103","article-title":"Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies","volume":"82","author":"Kaasinen","year":"2017","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13139-022-00748-4","article-title":"Prospective F-18 FDOPA PET imaging study in human PD","volume":"56","author":"Dhawan","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00259-005-1904-y","article-title":"Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease","volume":"33","author":"Eshuis","year":"2006","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1130","key":"10.1016\/j.ncl.2024.12.005_bib39","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210837","article-title":"Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT","volume":"95","author":"Takahashi","year":"2022","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ana.25026","article-title":"Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder","volume":"82","author":"Iranzo","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/brain\/awaa365","article-title":"Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder","volume":"144","author":"Arnaldi","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/acn3.51269","article-title":"Dopamine transporter imaging predicts clinically-defined alpha-synucleinopathy in REM sleep behavior disorder","volume":"8","author":"Chahine","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib43","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib44","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/mds.27777","article-title":"No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease","volume":"34","author":"Honkanen","year":"2019","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib45","first-page":"194","article-title":"Imaging in movement disorders","volume":"29","author":"Maiti","year":"2023","journal-title":"Continuum"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.005_bib46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mdc3.14055","article-title":"I(123)-FP-CIT (DaTSCAN) SPECT beyond the most common causes of parkinsonism: a systematic review","volume":"11","author":"Quintas","year":"2024","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib47","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1038\/s41467-024-49949-9","article-title":"Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions","volume":"15","author":"Zarkali","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib48","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/ejn.16296","article-title":"Neuromelanin-sensitive magnetic resonance imaging: possibilities and promises as an imaging biomarker for Parkinson's disease","volume":"59","author":"Yan","year":"2024","journal-title":"Eur J Neurosci"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib49","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/mrm.26584","article-title":"Contrast mechanisms associated with neuromelanin-MRI","volume":"78","author":"Trujillo","year":"2017","journal-title":"Magn Reson Med"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.005_bib50","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/mds.26201","article-title":"Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease","volume":"30","author":"Castellanos","year":"2015","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib51","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00330-020-07240-7","article-title":"Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis","volume":"31","author":"Cho","year":"2021","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12883-023-03350-z","article-title":"An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib53","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1093\/brain\/awab191","article-title":"The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease","volume":"144","author":"Biondetti","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2024.12.005_bib54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neulet.2016.09.011","article-title":"A\u00a0longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease","volume":"633","author":"Matsuura","year":"2016","journal-title":"Neurosci Lett"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.005_bib55","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/mds.28531","article-title":"Longitudinal changes in neuromelanin MRI signal in Parkinson's disease: a progression marker","volume":"36","author":"Gaurav","year":"2021","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib56","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.28934","article-title":"Neuromelanin-MRI to quantify and track nigral depigmentation in Parkinson's disease: a multicenter longitudinal study using template-based standardized analysis","volume":"37","author":"Xing","year":"2022","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.005_bib57","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.parkreldis.2014.04.005","article-title":"Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging","volume":"20","author":"Ohtsuka","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.005_bib58","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/mds.28988","article-title":"Regional selectivity of neuromelanin changes in the substantia nigra in atypical parkinsonism","volume":"37","author":"Chougar","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.005_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.parkreldis.2021.05.002","article-title":"Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia","volume":"87","author":"Matsuura","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib60","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamaneurol.2021.1312","article-title":"Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review","volume":"78","author":"Mitchell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.005_bib61","first-page":"4721","article-title":"Iron-sensitive magnetic resonance imaging in Parkinson's disease: a systematic review and meta-analysis","volume":"268","author":"Cho","year":"2021","journal-title":"J\u00a0Neurol"},{"issue":"Pt 8","key":"10.1016\/j.ncl.2024.12.005_bib62","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093814","article-title":"The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T","volume":"9","author":"Schwarz","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib64","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/mds.26932","article-title":"Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease","volume":"32","author":"Mahlknecht","year":"2017","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.005_bib65","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3174\/ajnr.A4412","article-title":"Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality","volume":"36","author":"Noh","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib66","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.26584","article-title":"Loss of nigral hyperintensity on 3 tesla MRI of parkinsonism: comparison with (123) I-FP-CIT SPECT","volume":"31","author":"Bae","year":"2016","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.005_bib67","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ana.24646","article-title":"Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder","volume":"79","author":"De Marzi","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1148\/radiol.2017162486","article-title":"Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: comparison with (123)I-FP-CIT SPECT","volume":"287","author":"Bae","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.ncl.2024.12.005_bib69","article-title":"Meta-analysis of iron metabolism markers levels of Parkinson's disease patients determined by fluid and MRI measurements","volume":"78","author":"Xu","year":"2023","journal-title":"J\u00a0Trace Elem Med Biol"},{"key":"10.1016\/j.ncl.2024.12.005_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.618435","article-title":"Systematic review: quantitative susceptibility mapping (QSM) of brain iron profile in neurodegenerative diseases","volume":"15","author":"Ravanfar","year":"2021","journal-title":"Front Neurosci"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib71","first-page":"899","article-title":"Magnetic resonance imaging assessment of substantia nigral iron deposition in Parkinson's disease: a meta-analysis","volume":"28","author":"Liu","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.005_bib72","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/mds.28077","article-title":"Magnetic susceptibility associates with dopaminergic deficits and cognition in Parkinson's disease","volume":"35","author":"Uchida","year":"2020","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib73","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/mds.29702","article-title":"Longitudinal associations of magnetic susceptibility with clinical severity in Parkinson's disease","volume":"39","author":"Thomas","year":"2024","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.005_bib74","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/mds.27318","article-title":"Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients","volume":"33","author":"Du","year":"2018","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.005_bib75","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/mds.27730","article-title":"Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease","volume":"34","author":"Bergsland","year":"2019","journal-title":"Mov Disord"},{"issue":"18","key":"10.1016\/j.ncl.2024.12.005_bib76","doi-asserted-by":"crossref","first-page":"18622","DOI":"10.18632\/aging.103870","article-title":"Asymmetrical nigral iron accumulation in Parkinson's disease with motor asymmetry: an explorative, longitudinal and test-retest study","volume":"12","author":"Guan","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"22","key":"10.1016\/j.ncl.2024.12.005_bib77","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of deferiprone in Parkinson's disease","volume":"387","author":"Devos","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson's disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxidants Redox Signal"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib79","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib80","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14607","article-title":"Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"30","author":"Negida","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib82","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","article-title":"Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease","volume":"74","author":"Gaiani","year":"2017","journal-title":"JAMA Neurol"},{"issue":"21","key":"10.1016\/j.ncl.2024.12.005_bib83","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mds.28847","article-title":"Neurofilament light chain predicts disease severity and progression in multiple system atrophy","volume":"37","author":"Zhang","year":"2022","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib85","first-page":"77","article-title":"Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson's disease","volume":"10","author":"Chen","year":"2020","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib86","first-page":"1117","article-title":"Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease","volume":"11","author":"Ma","year":"2021","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"13","key":"10.1016\/j.ncl.2024.12.005_bib87","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.005_bib89","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib90","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3233\/JAD-190615","article-title":"Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis","volume":"72","author":"Wang","year":"2019","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.005_bib91","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: a biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.005_bib92","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31517-z","article-title":"Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders","volume":"8","author":"Hall","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib94","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41531-021-00232-4","article-title":"Neurofilament light chain and alpha-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes","volume":"7","author":"Quadalti","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.ncl.2024.12.005_bib95","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","article-title":"Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)","volume":"90","author":"Niemann","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib96","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib97","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00702-022-02464-x","article-title":"Serum neurofilament light chain and postural instability\/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study","volume":"129","author":"Potter-Nerger","year":"2022","journal-title":"J\u00a0Neural Transm"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","article-title":"Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease","volume":"15","author":"Ng","year":"2020","journal-title":"Mol Neurodegener"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.005_bib99","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/mds.28779","article-title":"Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease","volume":"36","author":"Aamodt","year":"2021","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mds.28909","article-title":"Age-adjusted serum neurofilament predicts cognitive decline in Parkinson's disease (MARK-PD)","volume":"37","author":"Buhmann","year":"2022","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib101","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration","volume":"136","author":"Ishiki","year":"2016","journal-title":"J\u00a0Neurochem"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib102","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib103","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5607\/en21013","article-title":"Adenovirus-induced reactive astrogliosis exacerbates the pathology of Parkinson's disease","volume":"30","author":"An","year":"2021","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.ncl.2024.12.005_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.882316","article-title":"Astrocytes in neurodegeneration: inspiration from genetics","volume":"16","author":"Huang","year":"2022","journal-title":"Front Neurosci"},{"issue":"5\u20136","key":"10.1016\/j.ncl.2024.12.005_bib105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00702-022-02495-4","article-title":"Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease","volume":"129","author":"Gschmack","year":"2022","journal-title":"J\u00a0Neural Transm"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib106","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","article-title":"Biomarkers for Parkinson's disease: recent advancement","volume":"33","author":"Lotankar","year":"2017","journal-title":"Neurosci Bull"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib107","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","article-title":"Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients","volume":"114","author":"Su","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12916-023-03120-1","article-title":"Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study","volume":"21","author":"Lin","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","article-title":"Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia","volume":"9","author":"Tang","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.ncl.2024.12.005_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148271","article-title":"Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease","volume":"1805","author":"Mao","year":"2023","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib111","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson's disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.005_bib112","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.005_bib113","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013257","article-title":"Urinary proteome profiling for stratifying patients with familial Parkinson's disease","volume":"13","author":"Virreira Winter","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.27818","article-title":"Higher urine bis(Monoacylglycerol)Phosphate levels in LRRK2 G2019S mutation carriers: implications for therapeutic development","volume":"35","author":"Alcalay","year":"2020","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41531-023-00482-4","article-title":"Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's disease","volume":"9","author":"Gomes","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib116","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41531-023-00468-2","article-title":"LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts","volume":"9","author":"Merchant","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042286","article-title":"The impact of 90 Parkinson's disease-risk single nucleotide polymorphisms on urinary bis(monoacylglycerol)phosphate levels in the prodromal and PD cohorts","volume":"25","author":"Fang","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib118","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41531-022-00404-w","article-title":"Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort","volume":"8","author":"Simuni","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"273","key":"10.1016\/j.ncl.2024.12.005_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3634","article-title":"Effect of selective LRRK2 kinase inhibition on nonhuman primate lung","volume":"7","author":"Fuji","year":"2015","journal-title":"Sci Transl Med"},{"issue":"648","key":"10.1016\/j.ncl.2024.12.005_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib121","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147319","article-title":"An alzheimer's disease-derived biomarker signature identifies Parkinson's disease patients with dementia","volume":"11","author":"Berlyand","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib123","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11065-015-9307-8","article-title":"Do CSF biomarkers predict progression to cognitive impairment in Parkinson's disease patients? A systematic review","volume":"25","author":"Leaver","year":"2015","journal-title":"Neuropsychol Rev"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.005_bib124","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54204-z","article-title":"Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Abeta(1-42), pTau and tTau CSF immunoassays","volume":"9","author":"Blennow","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.005_bib126","first-page":"1155","article-title":"Appropriateness of applying cerebrospinal fluid biomarker cutoffs from alzheimer's disease to Parkinson's disease","volume":"12","author":"Weinshel","year":"2022","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib127","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal fluid alzheimer's disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort","volume":"54","author":"van Steenoven","year":"2016","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.005_bib128","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720510791383796","article-title":"The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia","volume":"7","author":"Spies","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"5\u20138","key":"10.1016\/j.ncl.2024.12.005_bib129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13195-014-0072-3","article-title":"Biomarkers in biological fluids for dementia with Lewy bodies","volume":"6","author":"Schade","year":"2014","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.005_bib130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/brain\/awac258","article-title":"Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease","volume":"146","author":"Blommer","year":"2023","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.005_bib131","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jnc.15601","article-title":"Plasma alpha-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease","volume":"161","author":"Ren","year":"2022","journal-title":"J\u00a0Neurochem"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib132","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A\u00a0biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.005_bib133","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A\u00a0biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"Hoglinger","year":"2024","journal-title":"Lancet Neurol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:55:03Z","timestamp":1750776903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861924001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0733861924001002"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.005","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}